LL-37

What is LL-37?

LL-37 is a 37-amino acid peptide that represents the only member of the cathelicidin family of antimicrobial peptides in humans. It is derived from the C-terminal cleavage of the precursor protein hCAP18 (human Cationic Antimicrobial Protein, 18 kDa) and was first identified in human neutrophils. The name derives from its two N-terminal leucine residues and its 37-residue length [1]. LL-37 is produced by neutrophils, macrophages, epithelial cells, and keratinocytes, particularly during infection and tissue injury.

The antimicrobial mechanism of LL-37 is primarily through membrane disruption. The peptide adopts an amphipathic alpha-helical structure that inserts into bacterial cell membranes, creating pores that lead to cell lysis. This mechanism provides broad-spectrum activity against gram-positive bacteria, gram-negative bacteria, fungi, and enveloped viruses [1]. Critically, LL-37 is effective against biofilm-forming organisms, including MRSA, Pseudomonas aeruginosa, and Candida species, which are notoriously resistant to conventional antibiotics [3].

Beyond direct antimicrobial activity, LL-37 functions as an immune modulator. It acts as a chemoattractant for neutrophils, monocytes, and T cells, recruits immune cells to infection sites, promotes angiogenesis and wound healing, and modulates inflammatory cytokine production [2]. Research has shown that LL-37 deficiency correlates with increased susceptibility to infections, particularly in chronic wounds, urinary tract infections, and respiratory infections [4]. These immunomodulatory properties have generated interest in LL-37 as a research compound for immune support and tissue repair applications.

Mechanism of Action

LL-37's biological activity spans direct antimicrobial effects, immune modulation, and tissue repair through several distinct but interconnected mechanisms:

Membrane Disruption (Direct Antimicrobial)

LL-37 adopts an amphipathic alpha-helical conformation in the presence of bacterial membranes. The positively charged face interacts with negatively charged bacterial lipopolysaccharides (gram-negative) or lipoteichoic acids (gram-positive), while the hydrophobic face inserts into the lipid bilayer. This creates transmembrane pores that dissipate the electrochemical gradient, causing osmotic lysis. The mechanism is rapid (minutes) and broadly effective because it targets the fundamental structural difference between prokaryotic and eukaryotic membranes [1].

Anti-Biofilm Activity

LL-37 disrupts established bacterial biofilms at concentrations below those required for planktonic killing. It interferes with initial bacterial attachment, disrupts quorum sensing signaling (las and rhl systems in P. aeruginosa), and promotes twitching motility that prevents organized biofilm architecture. This anti-biofilm activity is particularly significant because biofilm-associated infections are responsible for the majority of chronic and device-related infections [3].

Immune Cell Recruitment & Modulation

LL-37 acts as a chemoattractant through formyl peptide receptor-like 1 (FPRL1), recruiting neutrophils, monocytes, and T cells to infection sites. It modulates dendritic cell differentiation, promotes Th1-polarized immune responses, and influences the balance of pro- and anti-inflammatory cytokine production. At physiological concentrations, LL-37 enhances immune surveillance without provoking excessive inflammation [2].

Wound Healing & Angiogenesis

Research demonstrates that LL-37 promotes wound re-epithelialization through activation of the EGFR/STAT3 signaling pathway. The peptide stimulates keratinocyte migration, promotes angiogenesis at wound sites, and is upregulated during the normal wound healing process. Chronic wounds that fail to heal show diminished LL-37 expression, suggesting its role is critical for normal tissue repair [4].

Dosing Protocol

LL-37 dosing in the research context is based on preclinical data. Standard protocols use conservative doses given the peptide's potent biological activity and membrane-active properties.

Reconstitution Guide

Reconstitute lyophilized LL-37 with bacteriostatic water using strict sterile technique. LL-37 is more sensitive to degradation than many peptides; handle carefully and maintain cold chain.

1. Remove the plastic cap from the LL-37 vial and wipe the rubber stopper with an alcohol swab. Allow to dry.
2. Draw 2.5 mL of bacteriostatic water into a sterile syringe. For a 5 mg vial, this yields a concentration of 2,000 mcg/mL.
3. Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the peptide powder.
4. Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
5. The solution should be completely clear and colorless. Discard if you observe any cloudiness, particulate matter, or discoloration.

Injection Technique

LL-37 is administered via subcutaneous (SubQ) injection. Due to small injection volumes, a 0.3 mL or 0.5 mL insulin syringe provides better accuracy than a standard 1 mL syringe.

1. Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common sites: lower abdomen (2 inches from the navel), upper thigh, or proximal to the target area for wound healing protocols.
2. Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated number of units slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
3. Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45-degree angle in a quick, smooth motion. Release the skin fold.
4. Inject slowly. Depress the plunger steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab if needed.

Storage & Stability

LL-37 is less stable than many peptides due to its amphipathic structure and larger size (37 amino acids). Prompt use and strict cold chain maintenance are essential.

Side Effects & Considerations

LL-37's membrane-active properties mean side effects are more dose-dependent than with most peptides. Conservative dosing is recommended.

Commonly Reported

• Injection site reactions — redness, transient stinging, and mild swelling due to the peptide's membrane-active properties. May be more pronounced than with other peptides.
• Headache and mild flu-like symptoms — reported during initial use, likely related to immune activation.
• Mild fatigue — occasionally reported in the first few days of use.

Theoretical Considerations

• At high concentrations, LL-37 can exhibit cytotoxicity to mammalian cells; dosing should remain conservative.
• Potential for mast cell activation and histamine release at higher doses, which may cause localized flushing or itching.
• Overexpression of LL-37 has been associated with psoriasis and rosacea pathology; individuals with these conditions should exercise caution.
• Limited human safety data; dosing is extrapolated from preclinical research.

Stacking Protocols

LL-37 is sometimes studied alongside tissue-repair peptides, where its antimicrobial and immune-modulating properties complement the regenerative effects of other compounds.

LL-37 + BPC-157 (Immune Recovery Stack)

LL-37 provides antimicrobial defense and immune modulation while BPC-157 promotes tissue repair and angiogenesis. This combination targets both infection control and tissue regeneration.

Lifestyle Factors

Research suggests the following practices may support LL-37's immune and wound healing effects:

• Vitamin D: LL-37 expression is directly regulated by vitamin D through the vitamin D response element (VDRE) in the cathelicidin gene promoter. Adequate vitamin D status (40–60 ng/mL) supports endogenous LL-37 production.
• Sleep: Immune function and wound healing are optimized during deep sleep. Growth hormone release during sleep supports tissue repair processes.
• Zinc: Essential cofactor for immune cell function and wound healing. Supports the innate immune mechanisms that LL-37 enhances.
• Wound care: For wound healing protocols, maintain proper wound hygiene alongside LL-37 administration to prevent secondary infection.

Related Peptides

Researchers studying LL-37 often investigate these related compounds:

Literature & Citations

1. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280(1):22-35. PubMed
2. Duplantier AJ, van Hoek ML. The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds. Front Immunol. 2013;4:143. PubMed
3. Overhage J, Campisano A, Bains M, et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008;76(9):4176-4182. PubMed
4. Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. 2003;120(3):379-389. PubMed
5. Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013;191(10):4895-4901. PubMed
6. Kosciuczuk EM, Lisowski P, Jarczak J, et al. Cathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep. 2012;39(12):10957-10970. PubMed
7. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067-1077. PubMed